Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of α-smooth muscle actin

European Journal of Endocrinology

Volumn 163, Issue 4, 2010, Pages 691-697

  Cunningham, Janet L ^a   Tsolakis, Apostolos V ^a   Jacobson, Annica ^a   Janson, Eva T ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; PROTEIN HYDROLYSATE; ACTIN; CTGF PROTEIN, HUMAN;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX TUMOR; APPENDIX CARCINOID; ARTICLE; CARCINOID; CELL DIFFERENTIATION; CONTROLLED STUDY; ECLOMA TYPE 1; ECLOMA TYPE 3; ENDOCRINE TUMOR; FIBROBLAST; FIBROSIS; GOITER; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM CANCER; ILEUM CARCINOID; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; LUNG TUMOR; MAJOR CLINICAL STUDY; MYOFIBROBLAST; NEUROBLASTOMA; PANCREAS ISLET CELL TUMOR; PARATHYROID ADENOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RECTUM TUMOR; STROMA; THYROID ADENOMA; THYROID FOLLICULAR ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; TISSUE SECTION; TUMOR CELL; WESTERN BLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; SMOOTH MUSCLE;

ACTINS; BLOTTING, WESTERN; CARCINOID TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; ENDOCRINE GLAND NEOPLASMS; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH; IN VITRO TECHNIQUES;

EID: 77957147735     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0420     Document Type: Article

References (36)

1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P & Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 2008 9 61-72. (doi:10.1016/S1470-2045(07)70410-2)
2. Gustafsson BI, Tommeras K, Nordrum I, Loennechen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U & Waldum H. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005 111 1517-1522. (doi:10.1161/01.CIR.0000159356.42064.48) (Pubitemid 40470647)
3. Rameshwar P, Oh HS, Yook C, Gascon P & Chang VT. Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematologica 2003 109 1-10. (doi:10.1159/000067268)
4. Nilsson J, von Euler AM & Dalsgaard CJ. Stimulation of connective tissue cell growth by substance P and substance K. Nature 1985 315 61-63. (doi:10.1038/315061a0)
5. Katayama I & Nishioka K. Substance P augments fibrogenic cytokine-induced fibroblast proliferation: possible involvement of neuropeptide in tissue fibrosis. Journal of Dermatological Science 1997 15 201-206. (doi:10.1016/S0923-1811(97)00608-7) (Pubitemid 27390886)
6. Modlin IM, Shapiro MD & Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. American Journal of Gastroenterology 2004 99 2466-2478. (doi:10.1111/j.1572-0241.2004.40507.x)
7. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R & Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation 1998 28 1038-1049. (doi:10.1046/j.1365-2362.1998.00397.x) (Pubitemid 29050140)
8. Nilsson O, Wangberg B, McRae A, Dahlstrom A & Ahlman H. Growth factors and carcinoid tumours. Acta Oncologica 1993 32 115-124. (doi:10.3109/02841869309083899)
9. Zhang PJ, Furth EE, Cai X, Goldblum JR, Pasha TL & Min KW. The role of β-catenin, TGFβ3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Human Pathology 2004 35 670-674. (doi:10.1016/j.humpath.2003.12.010)
10. Grotendorst GR, Okochi H & Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth & Differentiation 1996 7 469-480.
11. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X & Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB Journal 1999 13 1774-1786.
12. Weston BS, Wahab NA & Mason RM. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. Journal of the American Society of Nephrology 2003 14 601-610. (doi:10.1097/01.ASN.0000051600.53134.B9)
13. Rachfal AW & Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatology Research 2003 26 1-9. (doi:10.1016/S1386-6346(03)00115-3)
14. Kidd M, Modlin IM, Shapiro MD, Camp RL, Mane SM, Usinger W & Murren JR. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World Journal of Gastroenterology 2007 13 5208-5216. (Pubitemid 47527737)
15. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods in Molecular Medicine 2005 117 69-80. (doi:10.1385/1-59259-940-0:069)
16. Leask A & Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB Journal 2004 18 816-827. (doi:10.1096/fj.03-1273rev)
17. Chaudhry A, Oberg K, Gobl A, Heldin CH & Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Research 1994 14 2085-2091.
18. Grotendorst GR, Rahmanie H & Duncan MR. Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB Journal 2004 18 469-479. (doi:10.1096/fj.03-0699com)
19. Grotendorst GR & Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB Journal 2005 19 729-738. (doi:10.1096/fj.04-3217com)
20. Solcia E, Klöppel G & Sobin LH. Histological Typing of Endocrine Tumours. WHO International Histological Classification of Tumours. Berlin: Springer, 2000.
21. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G & Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009 90 162-166. (doi:10.1159/000182196)
22. Yang DH, Kim HS, Wilson EM, Rosenfeld RG & Oh Y. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 1998 83 2593-2596. (doi:10.1210/jc.83.7. 2593)
23. Dziadzio M, Usinger W, Leask A, Abraham D, Black CM, Denton C & Stratton R. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. QJM: Monthly Journal of the Association of Physicians 2005 98 485-492. (doi:10.1093/qjmed/hci078) (Pubitemid 41418671)
24. Roestenberg P, van Nieuwenhoven FA, Wieten L, Boer P, Diekman T, Tiller AM, Wiersinga WM, Oliver N, Usinger W, Weitz S, Schlingemann RO & Goldschmeding R. Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy. Diabetes Care 2004 27 1164-1170. (doi:10.2337/diacare.27.5.1164)
25. Nielsen BS, Rank F, Illemann M, Lund LR & Dano K. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. International Journal of Cancer 2007 120 2086-2095. (doi:10.1002/ijc.22340)
26. De Wever O & Mareel M. Role of tissue stroma in cancer cell invasion. Journal of Pathology 2003 200 429-447. (doi:10.1002/path.1398) (Pubitemid 36818244)
27. Desmouliere A, Guyot C & Gabbiani G. The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. International Journal of Developmental Biology 2004 48 509-517. (doi:10.1387/ijdb.041802ad)
28. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K & Koeffler HP. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clinical Cancer Research 2004 10 2072-2081. (doi:10.1158/1078-0432.CCR-0659-03)
29. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang PC & Kuo ML. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. Journal of the National Cancer Institute 2004 96 364-375. (doi:10.1093/jnci/djh059)
30. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, Chau YP & Kuo ML. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005 128 9-23. (doi:10.1053/j.gastro.2004.10.007)
31. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, Ogawa A & Sawai T. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurological Research 2002 24 677-683. (doi:10.1179/016164102101200573)
32. Xie D, Nakachi K, Wang H, Elashoff R & Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Research 2001 61 8917-8923.
33. Moritani NH, Kubota S, Nishida T, Kawaki H, Kondo S, Sugahara T & Takigawa M. Suppressive effect of overexpressed connective tissue growth factor on tumor cell growth in a human oral squamous cell carcinoma-derived cell line. Cancer Letters 2003 192 205-214. (doi:10.1016/S0304-3835(02)00718-8)
34. Brigstock DR, Steffen CL, Kim GY, Vegunta RK, Diehl JR & Harding PA. Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids. Identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. Journal of Biological Chemistry 1997 272 20275-20282. (doi:10.1074/jbc.272.32.20275)
35. Kidd M, Modlin IM, Eick GN, Camp RL & Mane SM. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. American Journal of Physiology. Gastrointestinal and Liver Physiology 2007 292 G191-G200. (doi:10.1152/ajpgi.00131.2006) (Pubitemid 46090262)
36. Cunningham JL, Grimelius L, Sundin A, Agarwal S & Janson ET. Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncologica 2007 46 747-756. (doi:10.1080/ 02841860701218659)